Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,466 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT07162532 | Clinico-hematological and Molecular Characteristics of Chronic Lymphocytic Leukemia Patients | not yet recruiting | — | 45 | Assiut UniversityOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT07162571 |
| not yet recruiting |
| Phase 1 / Phase 2 |
| 17 |
| Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyOTHER_GOV |
| 1 |
| Sep 9, 2025 |
| clinicaltrials |
| NCT01863550 | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 3 | 1,087 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 8, 2025 | clinicaltrials |
| NCT07159906 | Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 62 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05372354 | A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 260 | Bristol-Myers SquibbINDUSTRY | 5 | Sep 5, 2025 | clinicaltrials |
| NCT05673083 | Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma | active not recruiting | — | 200 | All4CureINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07154537 | Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM) | active not recruiting | Phase 4 | 101 | National Taiwan University HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT04501939 | Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax(Venetoclax) | active not recruiting | Phase 2 | 5 | University of California, San DiegoOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06350994 | Early Assessment of Cardiac Function After Treatment With CAR-T Cells(Cardio CAR-T) | recruiting | — | 60 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07014865 | Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their Caregivers(MMYLIFE) | recruiting | — | 190 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Aug 29, 2025 | clinicaltrials |
| NCT07144657 | Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma(GastricMALToma) | not yet recruiting | Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT06882057 | Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol(CCCG-LR-B-ALL) | recruiting | Phase 2 / Phase 3 | 3,000 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 2 | Aug 26, 2025 | clinicaltrials |
| NCT06908629 | Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors | recruiting | N/A | 120 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT05607420 | Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma(NatHaLi-01) | recruiting | Phase 1 / Phase 2 | 80 | Cellectis S.A.INDUSTRY | 3 | Aug 24, 2025 | clinicaltrials |
| NCT07035379 | A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL | not yet recruiting | Phase 1 / Phase 2 | 66 | Zhejiang Teruisi Pharmaceutical Inc.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06446128 | A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) | recruiting | Early Phase 1 | 20 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Aug 21, 2025 | clinicaltrials |
| NCT05788081 | Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.(TOP-FLOR) | active not recruiting | Phase 2 | 40 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT06616389 | Study of ODX (OsteoDex) in Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 12 | DexTech Medical ABINDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT06664411 | Pola-ZR2P in Previously Untreated DLBCL | recruiting | Phase 2 | 80 | Navy General Hospital, BeijingOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07078500 | Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT06497738 | A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma | recruiting | — | 112 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07126678 | Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma | recruiting | N/A | 15 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT05565807 | Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 84 | Zhejiang ACEA Pharmaceutical Co. Ltd.INDUSTRY | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05779930 | Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL | not yet recruiting | Early Phase 1 | 12 | Nationwide Children's HospitalOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05913804 | YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07124936 | A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 97 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 15, 2025 | clinicaltrials |
| NCT03314181 | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 156 | AbbVieINDUSTRY | 7 | Aug 14, 2025 | clinicaltrials |
| NCT03765177 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies(CLIC-01) | recruiting | Phase 1 / Phase 2 | 60 | Ottawa Hospital Research InstituteOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05308654 | A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets | active not recruiting | Phase 1 | 34 | AbbVieINDUSTRY | 4 | Aug 14, 2025 | clinicaltrials |
| NCT06665217 | G-Pola-ZLP in Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 80 | Navy General Hospital, BeijingOTHER | 0 | Aug 14, 2025 | clinicaltrials |
| NCT06978088 | LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This | recruiting | Phase 2 | 34 | Zulfa OmerOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT02157324 | Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 12 | Acerta Pharma BVINDUSTRY | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07113496 | RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies | not yet recruiting | Phase 1 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT02734771 | A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)(BV mini CHP) | active not recruiting | Phase 2 | 24 | Patrick ReaganOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05667506 | A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) | recruiting | Phase 1 / Phase 2 | 47 | Juventas Cell Therapy Ltd.INDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07114432 | RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma | not yet recruiting | Phase 1 | 19 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT02393157 | Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL(O-ICE) | recruiting | Phase 2 | 25 | New York Medical CollegeOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT03314636 | Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.(CONPET) | active not recruiting | Phase 2 | 53 | Oslo University HospitalOTHER | 3 | Aug 8, 2025 | clinicaltrials |
| NCT05286229 | A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan | active not recruiting | Phase 1 | 8 | AbbVieINDUSTRY | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07111884 | GMMG Multiple Myeloma Registry | recruiting | — | 999 | Prof. Dr. Hartmut GoldschmidtOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07113132 | Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia | not yet recruiting | — | 84 | Safaa AliOTHER | 0 | Aug 8, 2025 | clinicaltrials |
| NCT06343311 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)(STARLIGHT-1) | recruiting | Phase 1 / Phase 2 | 21 | Estrella Biopharma, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07108868 | A Phase I Dose Finding Study of MB-CART2219.1 | recruiting | Phase 1 | 36 | University Hospital TuebingenOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06213636 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).(BAH241) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06365060 | Screening for AL Amyloidosis in Smoldering Multiple Myeloma | recruiting | — | 400 | Tufts Medical CenterOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106671 | A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106684 | ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia(CAREMM-004) | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Sep 9, 2025source: clinicaltrials